The ACCELERATE Trial

Recommendations

Info

Percent Change in HDL-C Levels During the <strong>Trial</strong> 175 Percent Change in HDL-C (%) 150 125 100 75 50 25 0 Mean HDL-C = 104 mg/dL Mean difference = 130% Mean HDL-C = 46 mg/dL Evacetrapib Placebo -25 0 4 8 12 16 20 24 28 32 Months Following Randomization Preliminary analysis prior to formal database lock
Percent Change in LDL-C Levels During the <strong>Trial</strong> 20 Percent Change in LDL-C (%) 10 0 -10 -20 -30 -40 Mean LDL-C = 84 mg/dL Mean difference 37% Mean LDL-C = 55 mg/dL Evacetrapib Placebo -50 0 4 8 12 16 20 24 28 32 Months Following Randomization Preliminary analysis prior to formal database lock
Page 1 and 2: The ACCELERATE Trial Impact of the
Page 3 and 4: Role of Cholesteryl Ester Transfer
Page 5 and 6: ACCELERATE Trial Design 12,092 pati
Page 7 and 8: Baseline Clinical Characteristics P
Page 9: Adherence and Retention Placebo (n=
Page 13 and 14: Secondary Efficacy Endpoints Placeb
Page 15 and 16: Systolic Blood Pressure During the
Page 17: ACCELERATE Data Sharing Initiative

The ACCELERATE Trial

Create successful ePaper yourself

Delete template?

Save as template?